Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02867709 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,686
- Enrollment target
NCT02867709: Completed Phase 3 study, sponsored by Allergan.
NCT02867709 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 1,686 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (118% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02867709, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,686 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
Primary Outcome
Pain freedom was defined as a reduction in headache pain severity from moderate/severe at baseline to no pain at 2 hours after the initial dose of investigational product. Participants were provided with electronic diary (eDiary) to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing postdose pain severity assessment at or before 2 hours after initial dose.
Interventions
- DRUG Ubrogepant
- DRUG Placebo-matching Ubrogepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,686 participants |
| Start Date | 2016-08-26 |
| Est. Completion | 2018-02-26 |
| Phase | Phase 3 |
What the finished NCT02867709 record still lists
NCT02867709 is an interventional study that assigns participants to a tested intervention. Its 1,686 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (118% higher).
The record links to 0 conditions, and to 2 interventions - of which Ubrogepant is the first listed.
NCT02867709 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02867709 about?
NCT02867709 is a clinical study titled "Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine". This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
What is the current status of trial NCT02867709?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,686 participants. The study started on 2016-08-26. Estimated completion is 2018-02-26.
What interventions are being tested in trial NCT02867709?
The interventions under investigation include: Ubrogepant (DRUG), Placebo-matching Ubrogepant (DRUG).
Who is sponsoring clinical trial NCT02867709?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02867709's enrollment target sits among peer trials
1,686 134th of 2000 higher than 1,867 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06376565 · 1,680 participants · NA
Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
- NCT06238622 · 1,700 participants · Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- NCT07284901 · 1,700 participants · Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI